MHC Class II-Restricted Antigen Presentation Is Required to Prevent Cytotoxic T-Cell Dysfunction by Blood-Borne Myeloids in Brain Tumors
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Cancer Cell
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
MHC class II-restricted antigen presentation is required to prevent dysfunction of cytotoxic T cells by blood-borne myeloids in brain tumors
Cancer Cell 2022 Dec 30;[EPub Ahead of Print], M Kilian, R Sheinin, CL Tan, M Friedrich, C Krämer, A Kaminitz, K Sanghvi, K Lindner, YC Chih, F Cichon, B Richter, S Jung, K Jähne, M Ratliff, RM Prins, N Etminan, A von Deimling, W Wick, A Madi, L Bunse, M PlattenFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Brain Cancer Center of Excellence
Visit our Brain Cancer Center of Excellence for additional, in-depth coverage.